Mechanisms of μ-opioid Receptor Inhibition of NMDA Receptor-induced Substance P Release in the Rat Spinal Cord
Overview
Pharmacology
Affiliations
The interaction between NMDA receptors and μ-opioid receptors in primary afferent terminals was studied by using NMDA to induce substance P release, measured as neurokinin 1 receptor internalization. In rat spinal cord slices, the μ-opioid receptor agonists morphine, DAMGO and endomorphin-2 inhibited NMDA-induced substance P release, whereas the antagonist CTAP right-shifted the concentration response of DAMGO. In vivo, substance P release induced by intrathecal NMDA after priming with BDNF was inhibited by DAMGO. ω-Conotoxins MVIIC and GVIA inhibited about half of the NMDA-induced substance P release, showing that it was partially mediated by the opening of voltage-gated calcium (Cav) channels. In contrast, DAMGO or ω-conotoxins did not inhibit capsaicin-induced substance P release. In cultured DRG neurons, DAMGO but not ω-conotoxin inhibited NMDA-induced increases in intracellular calcium, indicating that μ-opioid receptors can inhibit NMDA receptor function by mechanisms other than inactivation of Cav channels. Moreover, DAMGO decreased the ω-conotoxin-insensitive component of the substance P release. Potent inhibition by ifenprodil showed that these NMDA receptors have the NR2B subunit. Activators of adenylyl cyclase and protein kinase A (PKA) induced substance P release and this was decreased by the NMDA receptor blocker MK-801 and by DAMGO. Conversely, inhibitors of adenylyl cyclase and PKA, but not of protein kinase C, decreased NMDA-induced substance P release. Hence, these NMDA receptors are positively modulated by the adenylyl cyclase-PKA pathway, which is inhibited by μ-opioid receptors. In conclusion, μ-opioid receptors inhibit NMDA receptor-induced substance P release through Cav channel inactivation and adenylyl cyclase inhibition.
Basu P, Custodio-Patsey L, Prasoon P, Smith B, Taylor B J Neurosci. 2021; 41(47):9827-9843.
PMID: 34531285 PMC: 8612640. DOI: 10.1523/JNEUROSCI.2622-20.2021.
Baertsch N, Bush N, Burgraff N, Ramirez J Elife. 2021; 10.
PMID: 34402425 PMC: 8390004. DOI: 10.7554/eLife.67523.
Chen W, McRoberts J, Ennes H, Marvizon J Neuropharmacology. 2021; 189:108533.
PMID: 33744339 PMC: 8577816. DOI: 10.1016/j.neuropharm.2021.108533.
Chang C, Liu H, Yeh C, Yang M, Liao W, Liu C Int J Mol Sci. 2021; 22(4).
PMID: 33673008 PMC: 7918001. DOI: 10.3390/ijms22041891.
Chen W, Marvizon J Neuropharmacology. 2020; 177:108253.
PMID: 32736088 PMC: 10863619. DOI: 10.1016/j.neuropharm.2020.108253.